Open-House Biosimilar Discount Contracts 2026-05 - Pegfilgrastim

Auto-translated from Englisch

Original title: Open-House-Biologika-Rabattverträge 2026-05 - Pegfilgrastim

Techniker Krankenkasse

Published: Mar 19, 2026

Updated: May 9, 2026

Source: TED - Tenders Electronic Daily (EU)

Summary

Translated

The objective of this tender is to conclude drug discount contracts according to § 130a Abs. 8 SGB V (German Social Code Book V) for the active substance Pegfilgrastim. This will be conducted through an 'Open-House' procedure. Pegfilgrastim is a biosimilar medication used to stimulate the production of white blood cells, often prescribed to patients undergoing chemotherapy. The Open-House procedure allows multiple pharmaceutical companies to submit bids for discount contracts, promoting competition and potentially leading to cost savings for the healthcare system. The contracts will govern the supply and pricing of Pegfilgrastim, aiming to ensure its availability while achieving favorable economic terms for statutory health insurance providers in Germany.

Description

Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Pegfilgrastim im Rahmen eines Open-House-Verfahrens.

Find tenders like this automatically

Set up alerts and filters that match your business — never miss a relevant opportunity again.

See plans

About This Opportunity

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals and Health Financing. Located in Germany, Europe, this opportunity is open to firms and consortiums. Proposals must be submitted before April 29, 2028.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.